Structure and characterization of platinum(II) and platinum(IV) complexes with protonated nucleobase ligands

The reaction of H₂[PtCl₆] · 6H₂O and (H₃O)[PtCl₅(H₂O)] · 2(18C6) · 6H₂O (18C6 = 18-crown-6) with 9-methylguanine (MeGua) proceeded with the protonation of MeGua forming 9-methylguaninium hexachloroplatinate(IV) dihydrate (MeGuaH)₂[PtCl₆] · 2H₂O (1).The same compound was obtained from the reaction of Na₂[PtCl₆] with (MeGuaH)Cl.On the other hand, the reaction of guanosine (Guo) with (H₃O)[PtCl₅(H₂O)] · 2(18C6) · 6H₂O in methanol at 60 °C proceeded with the cleavage of the glycosidic linkage and with ligand substitution to give a guaninium complex of platinum(IV), [PtCl₅(GuaH)] · 1.5(18C6) · H₂O (2).Within several weeks in aqueous solution a slow reduction took place yielding the analogous guaninium platinum(II) complex, [PtCl₃(GuaH)] · (18C6) · 2Me₂CO (3).H₂[PtCl₆] · 6H₂O and guanosine was found to react in water, yielding (GuoH)₂[PtCl₆] (4) and in ethanol at 50 °C, yielding [PtCl₅(GuoH)] · 3H₂O (5).Dissolution of complexes 2 and 5 in DMSO resulted in the substitution of the guaninium and guanosinium ligands, respectively, by DMSO forming [PtCl₅(DMSO)]⁻.Reactions of 1-methylcytosine (MeCyt) and cytidine (Cyd) with H₂[PtCl₆] · 6H₂O and(H₃O)[PtCl₅(H₂O)] · 2(18C6) · 6H₂O resulted in the formation of hexachloroplatinates with N3 protonated pyrimidine bases as cation (MeCytH)₂[PtCl₆] · 2H₂O (6) and (CydH)₂[PtCl₆] (7), respectively. Identities of all complexes were confirmed by ¹H, ¹³C and ¹⁹⁵Pt NMR spectroscopic investigations, revealing coordination of GuoH⁺ in complex 5 through N7 whereas GuaH⁺ in complex 3 may be coordinated through N7 or through N9. Solid state structure of hexachloroplatinate 1 exhibited base pairing of the cations yielding (MeGuaH⁺)₂, whereas in complex 6 non-base-paired MeCytH⁺ cations were found. In both complexes, a network of hydrogen bonds including the water molecules was found. X-ray diffraction analysis of complex 3 exhibited a guaninium ligand that is coordinated through N9 to platinum and protonated at N1, N3 and N7. In the crystal, these NH groups form hydrogen bonds N–HO to oxygen atoms of crown ether molecules.     

Inhibition of peroxidase, trypsin, and alpha-chymotrypsin by platinum (II) and platinum (IV) complexes

Effects of various complexes of platinum (II) and platinum (IV) on activities of trypsin, alpha-chymotrypsin, and peroxidase were compared. The platinum (II) complexes were found to inhibit these enzymes, though with variable efficiency. The platinum (IV) complexes at concentrations < or = 0.2 mM efficiently inhibited peroxidase but had no effect on the proteases. An enzymatic assay was developed to measure the most effective peroxidase inhibitor (cisplatin) at concentrations of 5-50 microM in the presence of fivefold excess of its isomer (transplatin).     

Studies of the binding of a series of platinum(IV) complexes to plasma proteins

The platinum(IV) complexes: [PtCl(4)(en)], cis,trans-[PtCl(2)(OAc)(2)(en)], cis,trans-[PtCl(2)(OH)(2)(en)] and trans-[Pt(OH)(2)(ethmal)(en)], encompassing a range of reduction potentials and their platinum(II) analogue [PtCl(2)(en)], have been assayed for their protein binding ability in the presence of albumin, albumin and L-cysteine and RPMI 1640 tissue culture medium supplemented with foetal calf serum (RPMI/FCS). cis,trans-[PtCl(4)(en)] exhibited significant protein binding in all three experiments, in a similar fashion to the platinum(II) complex, presumably as a consequence of its rapid reduction. The remaining three platinum(IV) complexes displayed little if any protein binding, with the greatest amount of binding observed in the RPMI/FCS experiment. The extent of binding in the RPMI/FCS correlated with the reduction potentials of the complexes, with the most readily reduced species binding to the greatest extent.     

The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells

The cellular distribution of platinum in A2780 ovarian cancer cells treated with cisplatin and platinum(IV) complexes with a range of reduction potentials has been examined using elemental analysis (synchrotron radiation-induced X-ray emission). The cellular distribution of platinum(IV) drugs after 24 h is similar to that of cisplatin, consistent with the majority of administered platinum(IV) drugs being reduced. Micro-X-ray absorption near-edge spectra of cells treated with cisplatin and platinum(IV) complexes confirmed the reduction of platinum(IV) to platinum(II). In cells treated, the most difficult to reduce complex, cis,trans,cis-[PtCl₂(OH)₂(NH₃)₂], platinum(IV) was detected in the cells along with platinum(II). The observations are in accordance with the relative ease of reduction of the platinum(IV) complexes used and support the requirement of reduction for activation of platinum(IV) complexes.Abbreviations en ethane-1,2-diamine - GM growth medium - PBS phosphate buffered saline - RPMI Roswell Park Memorial Institute - SRIXE synchrotron radiation-induced X-ray emission - XAFS X-ray absorption fine structure - XANES X-ray absorption near-edge spectroscopy     

Interferon induction by platinum(II)-poly(I).poly(C) complexes

The effect of the interaction between poly(I).poly(C) and cis-dichloro-diammineplatinum(II) (cis-Pt), its trans analogue and chloro-diethylene-triamminoplatinum(II) (dien-Pt) on interferon induction activity was investigated. The covalent monodentate fixation of the three compounds on N7 of inosine has different effects on the structure and thermostability of poly(I). poly(C) which is well reflected by the interferon induction activity of the samples. Thus, the sandwich stabilization by dien-Pt at low binding ratios is manifested by an increased interferon induction and a high resistance towards RNAase degradation. The destabilization of the duplex by cis-Pt decreases interferon induction, accompanied by an increase in RNAase sensitivity of the complexes. In the case of trans-Pt the duplex structure is little perturbed and interferon induction is essentially maintained.     

Synthesis,characterization and antitumor activity of a series of N-substituted iminodiacetato(diammine) platinum(II) complexes

A series of water-soluble N-substituted iminodiacetato (diammine)platinum(II) complexes [Pt(NRIDA)(NH₃)₂] have been synthesized and characterized by measurement of physical properties (conductivity and pH) and by various spectroscopic techniques (infrared, ¹H and ¹³C{¹H} nuclear magnetic resonance). The iminodiacetate ligand is coordinated to platinum through an O,N linkage. The results obtained suggest that these complexes are relatively stable for more than 24 h in aqueous solution. Preliminary in vitro and in vivo screening test for antitumor activity of these complexes against L1210 murine leukemia were performed. Many of complexes had acceptable in vitro cytotoxicity, but none displayed a significant level of in vivo antitumor efficacy.     

Squarate complexes of diamine palladium(II) and platinum(II)

Reactions of cis-diaminediaqua palladium and platinum dinitrates and of trans-diaminediaqua platinum dinitrate give complexes of the type Pd(tmeda)(OH)(C₄O₄)Pd(tmeda)(C₄O₄H) (tmeda = tetramethylethylenediamine) (1), (en)M(C₄O₄)₂M(en) (en = ethylenediamine (M = Pd, Pt) and trans-[Pt- (NH₃)₂C₄O₄]_n, respectively. The structures of these compounds are discussed on the basis of their spectroscopic data.     

Palladium(II) and platinum(II) complexes with polypyridylbenzene ligands

The ligands 1,3-bis(3-pyridyl)benzene (1), 1,3-bis(4-pyridyl)benzene (2) and 1,3,5-tris(4-pyridyl)benzene (3) have been prepared by Stille coupling of 3- or 4-trimethylstannylpyridine with the appropriate bromoarene. Ligands 1 and 2 react with [M(OTf)₂(dppp)] (M=Pd, Pt) to produce the dipalladium- or diplatinum-containing macrocycles [M₂(μ-1)₂(dppp)₂](OTf)₄ or [M₂(μ-2)₂(dppp)₂](OTf)₄. These have been characterized by NMR spectroscopy and mass spectrometry and, in the case of [Pd₂(μ-1)₂(dppp)₂](OTf)₄, by X-ray crystallography. The molecular structure of the [Pd₂(μ-1)₂(dppp)₂]⁴⁺ cation reveals a shallow arrangement of the aromatic rings, with the palladium atoms lying above and below. The tridentate ligand 3 reacts with [Pd(OTf)₂(dppp)] to produce a trimetallic species of the form [Pd₃(μ₃-3)₂(dppp)₃](OTf)₆.     

Interferon induction by platinum(II)-poly(I)·poly(C) complexes

The effect of the interaction between poly(I)·poly(C) and cis-dichloro-diammineplatinum(II) (cis-Pt), its trans analogue and chloro-diethylene-triamminoplatinum(II) (dien-Pt) on interferon induction activity was investigated. The covalent monodentate fixation of the three compounds on N⁷ of inosine has different effects on the structure and thermostability of poly(I)·poly(C) which is well reflected by the interferon induction activity of the samples. Thus, the sandwich stabilization by dien-Pt at low binding ratios is manifested by an increased interferon induction and a high resistance towards RNAase degradation. The destabilization of the duplex by cis-Pt decreases interferon induction, accompanied by an increase in RNAase sensitivity of the complexes. In the case of trans-Pt the duplex structure is little perturbed and interferon induction is essentially maintained.     

Interactions between polynucleotides and platinum (II) complexes

Reaction of either $\text{cis}$ or $\text{trans}$ Pt(NH₃)₂Cl₂ with poly(A) in dilute aqueous solution leads to quantitative precipitation of the polymer at Pt/nucleotide ratios above 0.5. It is proposed that at ratios less than this, intramolecular binding of one Pt to two bases is favored; at higher ratios, intermolecular cross-linking becomes important and precipitation results. The absence of isomer selectivity in precipitation implies that the biological specificity of the $\text{cis}$ form results from a process other than cross-linking of polynucleotide strands. Other observations suggest that the coordinated ammonia of nucleotide-platinum(II) ammine complexes may be unusually labile.     

Synthesis, characterization and anti-tumour testing of some platinum(II) amine complexes containing 1,1- and 1,2-cyclobutanedicarboxylate ligands

A series of new platinum(II) amine complexes containing 1,1- and 1,2-cyclobutanedicarboxylate ligands, cis-[PtA2(1,1-CBDCA)] (A = RNH2, where R = C2H5, n-C3H7, n-C4H9, n-C5H11, n-C6H13, c-C3H5, c-C5H9, c-C6H11; A2 = ethylenediamine, 1,3-diaminopropane), cis-[PtA2(1,2-CBDCA)] (A = NH3, RNH2 where R = CH3, C2H5, n-C3H7, n-C4H9, c-C3H5) and trans-[Pt(NH3)2(1,1-CBDCAH)2] (CBDCA, CBDCAH = dianion and monoanion of the dicarboxylic acid, respectively) have been synthesized by an improved route. These complexes are stable in aqueous solution and show good aqueous solubility. The [Pt(c-C3H5NH2)2(1,1-CBDCA)] can be isolated in white, grey and blue forms. The grey and blue forms exhibit ESR signals analogous to the so-called platinum blues. The existence of the blue form in aqueous solution is time and temperature dependent. Several of the complexes have been tested against leukaemia L1210 in male BDF mice and activity appears to decrease with the increase in length of the aliphatic chain (or increase in size of the alicyclic ring) of the primary amine. The Yoshida lymphoscarcoma screen, usually insensitive to platinum drugs, was found to respond well to [Pt(n-C4H9NH2)2(1,1-CBDCA)] in 5-day subcutaneously implanted tumours in female Wistar rats.     

Toxicity, mutagenicity and induction of recA protein in Escherichia coli treated with cis-diamminedichloroplatinum(II) and cis-diamminetetrachloroplatinum(IV)

After exposure of bacteria to equal concentrations of cis-diamminedichloroplatinum(II) (DDP) and cis-diamminetetrachloroplatinum(IV) (DTP), the intracellular concentration of DTP was an order of magnitude greater than DDP. However, at identical intracellular drug concentrations, the Pt(IV) compound formed only half as many platinum-DNA lesions. For equal numbers of DNA lesions, the toxicity of both agents was identical whereas the mutagenicity of DTP was 7 times less than for DDP and its capacity to induce recA protein was less than DDP by a factor of 3.5. Bioreduction of Pt(IV) compounds to their corresponding Pt(II) analogues has been proposed as a mechanism for the reaction of Pt(IV) compounds with cellular DNA. According to this hypothesis, DTP would be reduced to DDP in the cell prior to its reaction with DNA and the platinum-DNA lesions of the two compounds should be identical. Our results suggest that reductive elimination can not entirely account for DNA damage caused by PT(IV) compounds in bacteria.     

Synthesis,characterization, cytotoxicity,and DNA binding of some new platinum(II) and platinum(IV) complexes with benzimidazole ligands

In this study, two Pt(II) and three Pt(IV) complexes with the structures of [PtL₂Cl₂] (1), [PtL₂I₂] (2), [PtL₂Cl₂(OH)₂] (3), [PtL₂Cl₂(OCOCH₃)₂] (4), and [PtL₂Cl₄] (5) (L = benzimidazole as carrier ligand) were synthesized and evaluated for their in vitro antiproliferative activities against the human MCF-7, HeLa, and HEp-2 cancer cell lines. The influence of compounds 1–5 on the tertiary structure of DNA was determined by their ability to modify the electrophoretic mobility of the form I and II bands of pBR322 plasmid DNA. The inhibition of BamH1 restriction enzyme activity of compounds 1–5 was also determined. In general, it was found that compounds 1–5 were less active than cisplatin and carboplatin against MCF-7 and HeLa cell lines (except for 1, which was found to be more active than carboplatin against the MCF-7 cell line). Compounds 1 and 3 were found to be significantly more active than cisplatin and carboplatin against the HEp-2 cell line.     

Steric influence on platinum(II) ascorbate complexes

From the reaction between dihydroxoplatinum(II) and l-ascorbic acid, two types of platinum(II) ascorbate complexes were obtained and structurally characterized with ethylenediamine (en), N,N-dimethylethylenediamine (dmen) and N,N,N′-trimethylethylenediamine (trimen) as stabilizing ligands. In [Pt(en)(asc-C,O)] (1), [Pt(dmen)(asc-C,O)] (2) and [Pt(trimen)(asc-C,O)] (4), the ascorbate dianion forms a five-membered chelate ring, coordinating to the Pt(II) ion at the 2-carbon and the 5-oxygen atoms (C,O-chelate). From the same mother solution, crystals of [Pt(trimen)(asc-O,O′)] (3) were obtained during the precipitation of 4; in 3 the ascorbate is bound to the Pt at the 2- and 3-oxygen atoms (O,O′-chelate). Compounds 3 and 4 are the first well-characterized linkage isomers among the transition-metal ascorbate complexes. The O,O′-chelated 3 slowly changes to the C,O-chelated 4 in an aqueous solution. Bulkiness of the stabilizing ligand, i.e. en, dmen and trimen has an influence on the formation of the C,O-chelated species, 1, 2 and 4.     

Reactions of platinum(IV) amine compounds with 9-methylhypoxanthine at high temperature result in both platinum(II) and platinum(IV) amine adducts

The products obtained from the reaction of Pt(IV)Cl₄(LL) compounds (LL denotes the chelating ligands ethylenediamine (en) and 2,2-dimethyl-1,3-diaminopropane (dmdap), or two cis- or trans-coordinated ammines) with 9-methylhypoxanthine (mHyp) at high temperature (80°C) have been characterized by proton NMR spectroscopy. It appeared that both platinum(II) and platinum(IV) adducts were present in the reaction mixtures. After cation-exchange chromatography, the Pt(II) compound could be characterized as Pt(II)(LL)(mHyp)₂, whereas the Pt(TV) fractions appeared to contain mainly one or two adducts for the chelating diamine compound but more adducts for the ammine compounds. A ³J(¹⁹⁵Pt-¹H) coupling was observed for the Pt(IV), but not for the Pt(II) compounds at the used spectrometer frequency. This supplies a useful tool to discriminate between these two types of platinum adducts.     

Water soluble platinum(II) and palladium(II) complexes of alkyl sulfonated phosphines

The reactions of the alkylsulfonated phosphines LM=Ph₂P(CH₂)_nSO₃Na/K (n=2, 3, 4) with K₂PtCl₄ and K₂PdCl₄ have been studied in homogeneous aqueous solution as a function of pH. In homogeneous acidic solution the protonated phosphines react to give cis- and trans-PtCl₂(LH)₂. The biphasic reaction between 1,5-cyclooctadiene platinum(II) chloride in dichloromethane and acidified aqueous LNa/K gives a higher proportion of the cis isomer. In neutral solution the initial reaction to give [PtCl(LNa/K)₃]⁺Cl⁻ is followed by slow formation of cis-PtCl₂(LNa/K)₂. K₂PdCl₄ reacts more rapidly to give PdCl₂(LNa/K)₂. In homogeneous alkaline solution rapid oxidation of the phosphine occurs with only small amounts of platinum complex being observable. The biphasic reaction yields phosphine oxide in the aqueous layer and a small amount of the chelate complexes PtL₂ in the organic. Representative complexes have been isolated and characterised and the mechanisms for the reactions discussed. The electrospray mass spectra of solutions of the isolated complexes have been recorded in both positive and negative ionisation modes. The positive ionisation spectra are complicated, but platinum and palladium containing ions derived from loss of chloride, H⁺ and HCl are observed in the negative ionisation spectra.     

The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours

SRIXE mapping has been used to gain insight into the fate of platinum(II) and platinum(IV) complexes in cells and tumours treated with anticancer active complexes to facilitate the development of improved drugs. SRIXE maps were collected of thin sections of human ovarian (A2780) cancer cells treated with bromine containing platinum complexes, cis-[PtCl(2)(3-Brpyr)(NH(3))] (3-Brpyr=3-bromopyridine) and cis,trans,cis-[PtCl(2)(OAcBr)(2)(NH(3))(2)] (OAcBr=bromoacetate), or a platinum complex with an intercalator attached cis-[PtCl(2)(2-[(3-aminopropyl)amino]-9,10-anthracenedione)(NH(3))]. After 24h the complexes appear to be localised in the cell nucleus with a lower concentration in the surrounding cytoplasm. In cells treated with cis-[PtCl(2)(3-Brpyr)(NH(3))] the concentration of bromine was substantially higher than in control cells and the bromine was co-localised with the platinum consistent with the 3-bromopyridine ligand remaining bound to the platinum. The cells treated with cis,trans,cis-[PtCl(2)(OAcBr)(2)(NH(3))(2)] also showed an increased level of bromine, but to a much lesser extent than for those treated with cis-[PtCl(2)(3-Brpyr)(NH(3))] suggestive of substantial reduction of the platinum(IV) complex. Maps were also collected from thin sections of a 4T1.2 neo 1 mammary tumour xenograft removed from a mouse 3h after treatment with cis,trans,cis-[PtCl(2)(OH)(2)(NH(3))(2)] and revealed selective uptake of platinum by one cell.     

Synthesis and cytotoxicity of new platinum(IV) complexes of mixed carboxylates

In order to develop new antitumor platinum(IV) complexes with highly tuned lipophilicity, a series of (diamine)Pt(IV) complexes of the formula [Pt(IV)(dach)L(3)L'] or [Pt(IV)(dach)L(2)L"(2)] (dach=trans-(+/-)-1,2-diaminocyclohexane; L=acetato, propionato; L'=acetato, propionato, valerato or pivalato; L"=trifluoroacetato) have been synthesized by electrophilic substitution of the tris(carboxylato)hydroxoplatinum(IV) complexes, [Pt(IV)(dach)L(3)OH] (L=acetato, propionato), with various carboxylic anhydrides such as acetic, trifluoroacetic, pivalic and valeric anhydrides. The present platinum(IV) complexes were fully characterized by means of elemental analyses, 1H NMR, mass and IR spectroscopies. The complexes 8 and 10, satisfying the appropriate range of lipophilicity (logP=0.18-1.54), exhibited high activity (ED(50), 5.1 and 1.3 microM, respectively) compared with other complexes, which implies that the lipophilicity is an important factor for the antitumor activity of this series of complexes.     

Synthesis and cytotoxic activity of benzopyran-based platinum(II) complexes

A series of benzopyran-based platinum complexes of types 4 and 5 were synthesized as potential anticancer agents. The novel compounds were synthesized in several steps using simple and efficient chemistry. The newly synthesized compounds were evaluated for their biological efficacy and showed significant in vitro cytotoxic activity in different hormone-dependent and -independent breast cancer cell lines. Docking and other molecular modeling experiments were also performed for one of the potent compounds, 5f, which showed that both the possible enantiomeric forms (5f with 3R,4R and 5f with 3S,4S) of the molecule have comparable lowest energy (for 5f with 3R,4R, −31.953 kcal/mol and for 5f with 3S,4S, −31.944 kcal/mol). The 3D QSAR was examined for the derivatives of both enantiomeric forms and a novel relationship for the 3S,4S derivatives is discussed.     

Synthesis, characterization and cytotoxicity of a series of tetrachloridoplatinum(IV) complexes

Two platinum(IV) complexes, [Pt(4bt)Cl₄] (4) and [Pt(dpyam)Cl₄]·DMF (5) (where 4bt is 4,4′-bithiazole and dpyam is 2,2′-dipyridylamine) were prepared from the reaction of H₂PtCl₆·6H₂O with 4,4′-bithiazole and 2,2′-dipyridylamine, respectively, in methanol. Both complexes were fully characterized and their structures were determined by the X-ray diffraction method. These complexes have a bidentate nitrogenous ligand with four chloride anions attached to a Pt(IV) metal in a distorted octahedral environment. These complexes along with three previously reported analogous complexes were used for in vitro cytotoxicity evaluation against four cultures, NIH-3T3, Caco-2, HT-29 and T47D by MTT assay. The methyl group position in the ligand plays an important role in the cytotoxicity of relevant compounds in different cultures. Interestingly, in some cases, the IC₅₀ values of the new complexes were higher for normal cells but lower against cancer cells in comparison with cisplatin, especially in T47D (breast ductal carcinoma).